The FDA posted documents on Monday flagging insufficient large-scale human trial data and potential safety issues for several peptides, with an advisory panel scheduled to review them in approximately three weeks. Robert F. Kennedy Jr., the current Health Secretary, received a November request from Rep. Diana Harshbarger to reevaluate six such compounds. Clinics including Maximus and Aether Medicine offer or promote these subcutaneous peptide treatments, and the FDA has issued at least one related warning letter.